These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 33145269)

  • 21. Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer.
    Ren Q; Zhu P; Zhang H; Ye T; Liu D; Gong Z; Xia X
    Cancer Cell Int; 2020; 20():92. PubMed ID: 32226313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
    Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 expression-related PI3K pathway correlates with immunotherapy efficacy in gastric cancer.
    Liu L; Niu L; Zheng X; Xiao F; Sun H; Deng W; Cai J
    Ther Adv Med Oncol; 2023; 15():17588359231205853. PubMed ID: 37868079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
    Liu J; Li H; Sun L; Yuan Y; Xing C
    Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
    Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
    Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
    Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
    BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A gastric cancer LncRNAs model for MSI and survival prediction based on support vector machine.
    Chen T; Zhang C; Liu Y; Zhao Y; Lin D; Hu Y; Yu J; Li G
    BMC Genomics; 2019 Nov; 20(1):846. PubMed ID: 31722674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Classification of gastric cancers based on immunogenomic profiling.
    Liu Z; Jiang Z; Wu N; Zhou G; Wang X
    Transl Oncol; 2021 Jan; 14(1):100888. PubMed ID: 33096337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
    Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
    Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new risk model based on a 11-m
    Lei L; Li N; Yuan P; Liu D
    BMC Cancer; 2022 Apr; 22(1):365. PubMed ID: 35382776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of genomic features associated with immunotherapy response in gastrointestinal cancers.
    He Y; Liu ZX; Jiang ZH; Wang XS
    World J Gastrointest Oncol; 2019 Apr; 11(4):270-280. PubMed ID: 31040893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical significance of PD-L1 in advanced gastric cancer is dependent on
    Buglioni S; Melucci E; Sperati F; Pallocca M; Terrenato I; De Nicola F; Goeman F; Casini B; Amoreo CA; Gallo E; Diodoro MG; Pescarmona E; Vici P; Sergi D; Pizzuti L; Di Lauro L; Mazzotta M; Barba M; Fanciulli M; Vitale I; De Maria R; Ciliberto G; Maugeri-Saccà M
    Oncoimmunology; 2018; 7(8):e1457602. PubMed ID: 30221053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of the Immune Cell Infiltration Landscape in Gastric Cancer to Assistant Immunotherapy.
    Li C; Pan J; Jiang Y; Yu Y; Jin Z; Chen X
    Front Genet; 2021; 12():793628. PubMed ID: 35069691
    [No Abstract]   [Full Text] [Related]  

  • 34. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer.
    Zhang C; Zhang M; Ge S; Huang W; Lin X; Gao J; Gong J; Shen L
    Cancer Med; 2019 Aug; 8(10):4766-4781. PubMed ID: 31243897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1/PD-L1 axis regulation in cancer therapy: The role of long non-coding RNAs and microRNAs.
    Ashrafizadeh M; Zarrabi A; Hushmandi K; Zarrin V; Moghadam ER; Zabolian A; Tavakol S; Samarghandian S; Najafi M
    Life Sci; 2020 Sep; 256():117899. PubMed ID: 32504749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
    Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
    BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.
    Kim ST; Klempner SJ; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Lee J
    Oncotarget; 2017 Sep; 8(44):77415-77423. PubMed ID: 29100397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Ferroptosis-Related lncRNAs Signature Predicts Prognosis and Therapeutic Response of Gastric Cancer.
    Xiao S; Liu X; Yuan L; Wang F
    Front Cell Dev Biol; 2021; 9():736682. PubMed ID: 34926441
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.